# US 2019/0374511 A1 · Oxymetazoline for the treatment of ano-rectal disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0374511 A1
- Document ID: US20190374511A1
- Status: Published application
- Kind: A1
- Application number: 16/547,120
- Filed: 2019-08-21
- Published: 2019-12-12
- Earliest claimed: 2011-04-26
- Assignees: RDD Pharma Ltd.
- Applicants: RDD Pharma Ltd.
- Inventors: Nir Barak; Howard Lawrence Rice
- Web page: https://patentgrep.com/patent/US20190374511A1

## CPC

- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 9/0031: {Rectum, anus}
- A61K 31/4164: 1,3-Diazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.

## Claims

### Claim 1

A method,
wherein the method treats fecal incontinence in a subject in need thereof,
wherein the method comprises: administering a therapeutically effective amount of a composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof to the subject's anal cavity, to treat the fecal incontinence,
wherein the therapeutically effective amount of the composition comprises 0.1% to 1% of oxymetazoline or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises oxymetazoline hydrochloride.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises at least one carrier, diluent, excipient, or combinations thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is selected from the group consisting of:
long acting, controlled release, slow release, sustained release, bioadhesive and mucoadhesive.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition is in a dosage form selected from the group consisting of: gel, cream, paste, spray suppository, mousse, emollient, powder, solution, suspension and foam.

### Claim 6 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition comprises 0.08% to 0.8% of oxymetazoline or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the composition comprising oxymetazoline or a pharmaceutically acceptable salt thereof is sufficient to treat fecal incontinence in the subject for at least 4 hours.
